Table 1.
Demographic Data in the Studied Patients
| Clinical Characteristics | No. of Cases (%) |
|---|---|
| Gender | |
| Male | 8 (61.5) |
| Female | 5 (38.5) |
| Median age (range) | 63 (33–75) |
| Site of metastasis | |
| Liver | 9 (69.2) |
| Lung | 7 (53.8) |
| Peritoneum | 4 (30.8) |
| Brain | 1 (7.7) |
| Number of sites of metastasis | |
| 1 | 6 (46.2) |
| 2 | 6 (46.2) |
| 3 | 1 (7.7) |
| KRAS status | |
| Wild type | 9 (69.2) |
| Mutation | 4 (30.8) |
| UGT1A1 status | |
| *1/*1 | 12 (92.3) |
| *1/*28 | 0 (0.0) |
| *28/*28 | 1 (7.7) |
| Irinotecan dose (mg/m2) | |
| 290 | 2 (15.4) |
| 260 | 2 (15.4) |
| 240 | 3 (23.1) |
| 210 | 1 (7.7) |
| 180 | 4 (30.8) |
| 120 | 1 (7.7) |
| Lines of systemic therapy | |
| Third | 4 (30.8) |
| Fourth | 7 (53.8) |
| Fifth | 2 (15.4) |
| Grade ≥3 adverse events | |
| Hand–foot syndrome | 8 (61.5) |
| Mucositis | 5 (38.5) |
| Neutropenia | 4 (30.8) |
| Diarrhea | 4 (30.8) |
| Fatigue | 3 (23.1) |
| Best objective response | |
| Partial response | 2 (15.4) |
| Stable disease | 7 (53.8) |
| Progressive disease | 4 (30.8) |